Neuroprotective effect of erythropoietin in amyotrophic lateral sclerosis (ALS) model in vitro. Ultrastructural study

Folia Neuropathologica

Volumn 48, Issue 1, 2010, Pages 35-44

  Nagańska, Ewa ^a   Taraszewska, Anna ^a   Matyja, Ewa ^a   Grieb, Pawel ^a   Rafałowska, Janina ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Erythropoietin; Excitotoxicity in vitro; Motor neuron degeneration; Neuroprotection

Indexed keywords

ERYTHROPOIETIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; IN VITRO STUDY; LUMBAR SPINAL CORD; MOTONEURON; NERVE CELL DEGENERATION; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; ORGAN CULTURE; POSTSYNAPTIC POTENTIAL; RAT; ULTRASTRUCTURE;

EID: 77950819882     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Adamcio B, Sargin D, Stradomska A, Medrihan L, Gertler C, Theis F, Zhang M, Müller M, Hassouna I, Hannke K, Sperling S, Radyushkin K, El-Kordi A, Schulze L, Ronnenberg A, Wolf F, Brose N, Rhee JS, Zhang W, Ehrenreich H. Erythropoietin enhances hippocampal long-term potentiation and memory. BMC Biol 2008; 9: 37.
2. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, Ghezzi P. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002; 11: 128-314. (Pubitemid 35279495)
3. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141: 14-31.
4. Bianchi R, Brines M, Lauria G, Savino C, Gilardini A, Nicolini G, Rodriguez-Menendez V, Oggioni N, Canta A, Penza P, Lombardi R, Minoia C, Ronchi A, Cerami A, Ghezzi P, Cavaletti G. Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res 2006; 12: 2607-2612.
5. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000; 97: 10526-10531.
6. Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M, Corica F, Frisina. The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 2003; 62: 228-236. (Pubitemid 36330674)
7. Campana WM, Myers RR. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J 2001; 15: 1804-1806.
8. Campana WM, Myers RR. Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury. Eur J Neurosci 2003; 18: 1497-1506.
9. Celik M, Gökmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, Genc S, Genc K, Sagiroglu E, Cerami A, Brines M. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 2002; 99: 2258-2263. (Pubitemid 34169048)
10. Ehrenreich H, Bartels C, Sargin D, Stawicki S, Krampe H. Recombinant human erythropoietin in the treatment of human brain disease: focus on cognition. J Ren Nutr 2008; 18: 146-153. (Pubitemid 350251844)
11. Eid T, Brines ML, Cerami A, Spencer DD, Kim JH, Schweitzer JS, Ottersen OP, de Lanerolle NC. Increased expression of erythropoietin receptor on blood vessels in the human epileptogenic hippocampus with sclerosis. J Neuropathol Exp Neurol. 2004; 63: 73-83. (Pubitemid 38030235)
12. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissueprotective cytokine. Cell Death Differ 2004; Suppl 1: S37-S44.
13. Grasso G, Sfacteria A, Passalacqua M, Morabito A, Buemi M, Macri B, Brines ML, Tomasello F. Erythropoietin and erythropoietin receptor expression after experimental spinal cord injury encourages therapy by exogenous erythropoietin. Neurosurgery 2005; 56: 821-827. (Pubitemid 40489758)
14. Grasso G, Sfacteria A, Meli F, Passalacqua M, Fodale V, Buemi M, Giambartino F, Iacopino DG, Tomasello F. The role of erythropoietin in neuroprotection: therapeutic perspectives. Drug News Perspect 2007; 20: 315-320. (Pubitemid 47345223)
15. Koh SH, Kim Y, Kim HY, Cho GW, Kim KS, Kim SH. Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation. Eur J Neurosci 2007; 25: 1923- 1930. (Pubitemid 46581743)
16. Koshimura K, Murakami Y, Sohmiya M, Tanaka J, Kato Y. Effects of erythropoietin on neuronal activity. J Neurochem 1999; 72: 2565-2572. (Pubitemid 29242209)
17. Lauria G, Campanella A, Filippini G, Martini A, Penza P, Maggi L, Antozzi C, Ciano C, Beretta P, Caldiroli D, Ghelma F, Ferrara G, Ghezzi P, Mantegazza R. Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotroph Lateral Scler 2009; 10: 410-415.
18. Liu XB, Wang JA, Yu SP, Keogh CL, Wei L. Therapeutic strategy of erythropoietin in neurological disorders CNS Neurol Disord Drug Targets 2008; 7: 227-234.
19. Lykissas MG, Korompilias AV, Vekris MD, Mitsionis GI, Sakellariou E, Beris AE. The role of erythropoietin in central and peri pheral nerve injury. Clin Neurol Neurosurg 2007; 109: 639-644. (Pubitemid 47248036)
20. Matyja E, Taraszewska A, Nagańska E, Rafałowska J. Autophagic degeneration of motor neurons in a model of slow glutamate excitotoxicity in vitro. Ultrastruct Pathol 2005; 29: 331-339. (Pubitemid 41577213)
21. Matyja E, Nagańska E, Taraszewska A, Rafałowska J. The mode of spinal motor neurons degeneration in a model of slow glutamate excitotoxicity in vitro. Folia Neuropathol 2005; 43: 7-13. (Pubitemid 40533187)
22. Matyja E, Taraszewska A, Naganska E, Rafałowska J, Gebarowska J. Astroglial alterations in amyotrophic lateral sclerosis (ALS) model of slow glutamate excitotoxicity in vitro. Folia Neuropathol 2006; 44: 183-190. (Pubitemid 44613892)
23. Matyja E, Taraszewska A, Nagańska E, Grieb P, Rafałowska J. CDP-choline protects motor neurons against apoptotic changes in a model of chronic glutamate excitotoxicity in vitro. Folia Neuropathol 2008; 46: 139-148.
24. Maurer MH, Schäbitz WR, Schneider A. Old friends in new constellations - the hematopoetic growth factors G-CSF, GM-CSF, and EPO for the treatment of neurological diseases. Curr Med Chem 2008; 15: 1407-1411. (Pubitemid 351997791)
25. Morishita E, Maruda S, Nagao M, Yasuda Y. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997; 76: 105-116. (Pubitemid 26407940)
26. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage Proc Natl Acad Sci U S A 1998; 95: 4635-4640. (Pubitemid 28207965)
27. Sasaki R. Pleiotropic functions of erythropoietin. Intern Med 2003; 42: 142-149. (Pubitemid 36372351)
28. Sekiguchi Y, Kikuchi S, Myers RR, Campana WM. ISSLS prize winner: Erythropoietin inhibits spinal neuronal apoptosis and pain following nerve root crush. Spine (Phila Pa 1976) 2003; 28: 2577-2584. (Pubitemid 37490466)
29. Sinor AD, Greenberg DA. Erythropoietin protects cultured cortical neurons, but not astroglia, from hypoxia and AMPA toxicity. Neurosci Lett 2000; 290: 213-215.
30. Sirén AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 2001; 98: 4044-4049. (Pubitemid 32249895)
31. Yoo JY, Won YJ, Lee JH, Kim JU, Sung IY, Hwang SJ, Kim MJ, Hong HN Neuroprotective effects of erythropoietin posttreatment against kainate-induced excitotoxicity in mixed spinal cultures. J Neurosci Res 2009; 87: 150-163.